Six The phosphodiesterase-five inhibitor sildenafil is licensed for PAH in FC I–IV within the United states of america and FC II–III in Europe. Endothelin receptor antagonists (ERAs) like bosentan, sitaxentan and ambrisentan are oral therapies certified to be used in PAH. As no oral agent has revealed superiority there remains https://tracleer72603.is-blog.com/32191969/details-fiction-and-tracleer